19 Oct 2011:Reference is made to NorDiag ASA's (the "Company") stock exchange announcement 12 October 2011 regarding [...]

19 Oct 2011: NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES.

Reference is made to NorDiag ASA's (the "Company") stock exchange announcement 12 October 2011 regarding the established underwriting and new terms proposed in NOK 15 to 20 million rights issue.

It was a condition for the underwriting of the rights issue that the Company obtained bridge financing in the period until completion of the rights issue. The bridge financing has now been obtained.

Contact:
CEO Mårten Wigstøl                 Tel: +47 911 65775
CFO Tone Kvåle                       Tel: +47 915 19576

About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions (instruments and reagents) for sample preparation of DNA from difficult biological samples. DNA diagnostics give more rapid and precise answers, and are the fastest growing field within diagnostics. The Company's sample preparation solutions are today used in connection with STI, tuberculosis, MRSA, respiratory pathogens and viruses on instruments for large and small laboratories. NorDiag was founded in 2003 and has its headquarters in Oslo, Norway. The Company has offices and laboratories in Stockholm, Sweden and in Atlanta (GA), USA. The group has today 31.6 man-labour years. NorDiag is listed on the Oslo Stock Exchange with ticker NORD.
 
For further information - www.nordiag.com

Read the notice in Norwegian here